A recent cross-border acquisition by Anhui Hongyu Wuzhou Medical Manufacturer Co.,Ltd. (SZSE: 301234) has sent its stock price soaring, recording four consecutive "20cm" limit-up days after the trading halt was lifted. From July 22 to July 27, 2026, the company's share price more than doubled.
Wuzhou Medical primarily focuses on the R&D, manufacturing, and sale of sterile disposable infusion devices, along with the integrated supply of other diagnostic and care-related medical products. The acquisition target, Xuanzhi Technology, operates in the chip design sector. The size of the target's earnings raises questions about why the stock is being heavily speculated upon.
The target's financial scale is modest and has only just returned to profit.
On July 22, Wuzhou Medical announced a plan to acquire 100% of Xuanzhi Technology through a combination of share issuance and cash payment. It also plans to raise matching funds from specific investors. Xuanzhi Technology, a spin-off from Fairchild Semiconductor's motor control product line, has shipped over 200 million chips for use in drones, home appliances, industrial controls, and automotive electronics.
Wuzhou Medical listed on the A-share market in 2022, but its performance peaked that year. From 2022 to 2025, revenue fell from 547 million yuan to 458 million yuan, while net profit attributable to shareholders dropped from 70.93 million yuan to 18.89 million yuan. The company has cited increased market competition, falling product prices, and currency fluctuations as reasons for its decline. This raises the question of whether this acquisition can genuinely improve the quality of the listed company given its weak fundamentals.
Xuanzhi Technology itself only turned profitable last year. In 2024, it posted a net loss of 41.85 million yuan on revenue of 158 million yuan. In 2025, revenue grew to 258 million yuan, yielding a net profit of 32.79 million yuan. While revenue is growing quickly, the stability of its profitability remains to be seen, with net profit margins fluctuating from -26% in 2024 to 13% in 2025 and 11% in the first half of 2026.
Is Yuanhe Puhua orchestrating a new arbitrage strategy for A-share companies?
A notable aspect of this deal is the simultaneous share issuance and a separate block trade agreement. The controlling shareholder of Wuzhou Medical and other parties agreed to sell 11.8% of the company's shares to Jiaxing Huixin, an entity affiliated with Yuanhe Puhua, at a price of 48.53 yuan per share, totaling about 390 million yuan. Yuanhe Puhua is itself a 4.04% shareholder in Xuanzhi Technology, making this a related-party transaction.
Two key points emerge from this structure. First, Jiaxing Huixin, acting on behalf of the target's shareholder Yuanhe Puhua, will take a significant stake in the listed company (over 11.8%) and is entitled to nominate a director. Second, Yuanhe Puhua is a deep-pocketed semiconductor industry investor, having backed nearly 50 listed chip companies like Will Semiconductor and Empyrean Technology.
This raises several questions: Why is the acquisition paired with a block trade that brings in a specific industry capital background investor? Does this "block trade + asset injection" strategy create inflated market expectations? What role does Yuanhe Puhua play in the deal, and does the large stake transfer constitute a "three-party transaction"?
This combined approach may offer Yuanhe Puhua multiple benefits. As an early investor in Xuanzhi Technology, it opens a new "asset securitization" exit channel for its fund. More critically, the structural price gap between the high-priced block trade (48.53 yuan) and the low-priced share swap for the target asset (31.40 yuan) allows for significant arbitrage. With Wuzhou Medical's stock surging 128% in recent trading days, the block trade position is already floating over 60% in profit, while the swapped shares have gained nearly 150%. The actual returns, factoring in Yuanhe Puhua's initial low-cost investment, could be far higher.
Is this a new pattern for targeting listed companies?
This same playbook appears to have been used previously by Yuanhe Puhua. In November 2025, Mengtian Home announced a plan to acquire Chuanwei Micro through a share and cash deal, alongside a controlling stake change. While that asset injection was terminated, Yuanhe Puhua's affiliate, Jiaxing Huixin, still executed a block trade to acquire a 6.86% stake in Mengtian Home at 17.46 yuan per share. Following the announcement, Mengtian Home's stock price exploded, rising from 15.56 yuan to a peak of 58.31 yuan, nearly tripling in value. This suggests a recurring pattern where the introduction of a specific industry capital partner, combined with the prospect of asset injection, fuels a market frenzy and enables a profitable exit.
Comments